Form 8-K - Current report:
SEC Accession No. 0001999371-25-018430
Filing Date
2025-11-24
Accepted
2025-11-24 07:06:15
Documents
14
Period of Report
2025-11-24
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_112425.htm   iXBRL 8-K 28156
2 PRESS RELEASE ex99-01.htm EX-99.01 41516
6 GRAPHIC tonixlogo.jpg GRAPHIC 7265
  Complete submission text file 0001999371-25-018430.txt   259287

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnxp-20251124.xsd EX-101.SCH 3023
4 XBRL LABEL FILE tnxp-20251124_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE tnxp-20251124_pre.xml EX-101.PRE 22364
16 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_112425_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 251509559
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)